Long-Term Response to SARS-CoV-2 mRNA Vaccine in Adolescents

The Pediatric Infectious Disease Journal, Год журнала: 2025, Номер unknown

Опубликована: Янв. 28, 2025

Background: The COVID-19 pandemic’s transition to an endemic phase emphasizes the importance of vaccination. Despite initial strong immunogenicity, waning vaccine-induced immunity requires further investigation. Therefore, this study evaluated immunogenicity BNT162b2 vaccine in adolescents, focusing on spike-specific and neutralizing antibody kinetics following primary booster vaccinations as well impact breakthrough infections. Methods: This observational included 157 adolescents 12–17 years old who received 22 participants doses. Antibody levels were measured at 1, 3, 5 10 months post-vaccination post-booster. Breakthrough infections identified using SARS-CoV-2 antigen/polymerase chain reaction tests. Safety was monitored by tracking adverse effects. Results: Post-primary vaccination, geometric mean titer anti-spike antibodies decreased significantly over time, with a 2.3-fold reduction after months. Booster doses induced higher titers, which also waned albeit more slowly. boosted including those against variants such Delta Omicron. Long-term effects minimal, only 7 cases transient lymph node enlargement menstrual irregularities. Conclusions: robust immune responses adolescents; however, time. are essential for sustained protection, especially emerging variants. enhance responses, highlighting benefits hybrid immunity. safety profile is generally favorable; ongoing monitoring warranted.

Язык: Английский

---

Immunogenicity of Monovalent mRNA-1273 and BNT162b2 Vaccines in Children <5 Years of Age

PEDIATRICS, Год журнала: 2024, Номер 153(6)

Опубликована: Март 29, 2024

BACKGROUND AND OBJECTIVES The messenger RNA (mRNA)-based coronavirus disease 2019 vaccines approved for use in children <5 years of age have different antigen doses and administration schedules that could affect vaccine immunogenicity effectiveness. We sought to compare the strength breadth serum binding neutralizing antibodies severe acute respiratory syndrome 2 (SARS-CoV-2) elicited by monovalent mRNA-based young children. METHODS conducted a prospective cohort study 6 months 4 who completed primary series vaccination with mRNA-1273 or BNT162b2 vaccines. Serum was collected 1 month after completion measurement SARS-CoV-2-specific humoral immune responses, including antibody responses Spike proteins from an ancestral strain (D614G) major variants SARS-CoV-2 activity against D614G Omicron subvariants (BA.1, BA.4/5). RESULTS Of 75 participants, 40 (53%) received 35 (47%) BNT162b2. Children receiving either developed robust broad antibodies, subvariants. previous history infection significantly higher neutralization titers subvariants, which is consistent occurrence identified infections during circulation region. CONCLUSIONS Monovalent similar In addition, enhanced authors future studies should evaluate incorporation these into standard childhood immunization schedule.

Язык: Английский

---

Evolution of the Antigenic Landscape in Children and Young Adults with COVID-19 and MIS-C

Vaccines, Год журнала: 2024, Номер 12(6), С. 638 - 638

Опубликована: Июнь 7, 2024

There is minimal knowledge regarding the durability of neutralization capacity and level binding antibody generated against highly transmissible circulating Omicron subvariants following SARS-CoV-2 infection in children with acute COVID-19 those diagnosed multisystem inflammatory syndrome (MIS-C) absence vaccination. In this study, titers ancestral strain (WA1) sublineages were evaluated unvaccinated admitted for (n = 32) MIS-C at time hospitalization (baseline) six to eight weeks post-discharge (follow-up) between 1 April 2020, September 2022. addition, spike receptor domain (RBD) from WA1, BA.1, BA.2.75, BA.4/BA.5 was determined using surface plasmon resonance (SPR). At baseline, demonstrated two-fold three-fold higher neutralizing antibodies WA1 compared COVID-19. Importantly, COVID-19, virus reached same as had baseline but than 6–8 cases. Cross-neutralization recently emerged BQ.1, BQ.1.1, XBB.1 variants very low either or all points. These findings about post-infection immunity suggest need vaccinations prior provide effective protection emerging variants.

Язык: Английский

---

Timeline of the pandemic: epidemiology, global spread, variants and waves

European Respiratory Society eBooks, Год журнала: 2024, Номер unknown

Опубликована: Авг. 27, 2024

Язык: Английский

---